Business
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
MOUNTAIN VIEW, Calif., March 19, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce a presentation of a new pre-clinical clinical data abstract at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting.
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/05cb5c77b42f034c910efb3c50fec5d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p0tEl9okxtGFUFkdsCBT.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/05cb5c77b42f034c910efb3c50fec5d4","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/oFJrVexJxWWu2GmcHkLJHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/05cb5c77b42f034c910efb3c50fec5d4","width":1024,"height":512}},"lazy":false},{"type":"text","content":"New human pharmacokinetic (PK) and other pre-clinical data supports use of RenovoRx’s novel Trans-Arterial Micro-Perfusion (TAMP™) therapy platform","length":147,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., March 19, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce a presentation of a new pre-clinical clinical data abstract at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting.","length":439,"tagName":"p"},{"type":"text","content":"The abstract, titled "Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Locally Advanced Pancreatic Cancer: Results of a Phase III Randomized Clinical Trial," is co-authored by Dr. Ramtin Agah, RenovoRx’s Chief Medical Officer. The abstract supports RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform via additional human PK data and pre-clinical data.","length":407,"tagName":"p"},{"type":"text","content":"TAMP is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to locoregional treatment offers the potential for increased safety, tolerance, and improved efficacy.","length":346,"tagName":"p"},{"type":"text","content":"RenovoRx’s ongoing Phase III TIGeR-PaC clinical tr...